Article citationsMore>>

Ramasamy, M.N., Minassian, A.M., Ewer, K.J., et al. (2020) Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial. Lancet, 396, 1979-1993. https://doi.org/10.1016/S0140-6736(20)32466-1

has been cited by the following article:

• TITLE: Guillain-Barré Syndrome Following AstraZeneca COVID-19 Vaccine

  AUTHORS: Ali Mikdad Hassan, Syeda Marium, Paras Yousuf, Asad Akram Farooqi, Uzair Yaqoob

  KEYWORDS: COVID-19, Coronavirus, Vaccination, Guillain-Barre Syndrome, AstraZeneca

  JOURNAL NAME: Open Access Library Journal, Vol.9 No.11, November 25, 2022

  ABSTRACT: It’s been more than two years since the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China, in December 2019, and still Coronavirus-19 (COVID-19) is an ongoing burden in many parts of the world. Currently, few vaccines are approved by the World Health Organization (WHO) and are being administered to people to boost their immunity. Since the outbreak of this disease, the number of patients getting vaccinated is increasing with every passing day. Understanding the burden of the disease and the adverse effects due to its vaccination is very crucial. We report a case of Guillain-Barre Syndrome after receiving the first dose of the AstraZeneca-COVID-19 vaccine.